Rapid foot and calf compression increases walking distance in patients with intermittent claudication: Results of a randomized study  by Ramaswami, Ganesh et al.
Rapid foot and calf compression increases walking
distance in patients with intermittent claudication:
Results of a randomized study
Ganesh Ramaswami, MD, PhD, Marcus D’Ayala, MD,a Larry H. Hollier, MD,b Reena Deutsch, PhD,c
and A. James McElhinney, MD,d Houston, Tex; Brooklyn and Bronx, NY; New Orleans, La; and San Diego,
Calif
Objective: The aim of our pilot study was to determine the usefulness of rapid, high-pressure, intermittent pneumatic calf
and foot compression (IPCFC) in patients with stable intermittent claudication, with reference to the end points of
improvement in initial claudication distance (ICD) (distance at which patient feels pain or discomfort in the legs), and
improvement in absolute claudication distance (ACD) (distance at which patient stops walking because the pain or
discomfort becomes severe).
Methods: Thirty male patients presenting with stable, intermittent claudication (ACD between 50 and 150 meters on
treadmill testing at 3.8 km/h, 10° gradient) were recruited into this pilot study from a single center. Fifteen patients were
randomized to treatment with IPCFC (applied for 1 hour twice daily in the sitting position) and were also advised to have
daily exercise, and 15 patients served as controls, who were advised exercise alone. All patients received aspirin and had
resting and postexercise ankle/brachial index (ABI) measured at enrollment along with ICD and ACD on treadmill
testing (3.8 km/h, 10° gradient). The mean age, baseline ICD, and ACD of the treatment and control groups were 70.4
 7 years and 70.7  9 years, 55.8  15 meters and 68.4  17 meters, and 86.7  19 meters and 103.9  27 meters,
respectively. Both groups were equally matched for risk factors, including smoking, type II diabetes mellitus, and
hypercholesterolemia. IPCFC was applied. The study protocol included follow-up visits at 1, 2, 3, 4, 6, and 12 months
with the ABI, ICD and ACD being measured at every visit.
Results: The percent change from baseline for ICD and ACD for each patient visit and the mean  standard deviation
(SD), standard error (SE), and median were calculated for the control and treatment groups. The percent change from
baseline measurements (mean  SD) for ICD and ACD in the control group at 4, 6, and 12 months were 2.2  18 and
2.3  18, 2.9  17 and 5.2  20, and 3.6  18 and 5.8  20, respectively. In contrast, the changes in ICD and ACD at
4, 6, and 12 months in the treatment group were 137.1  128 (P < .01) and 84.3  82 (P < .01), 140.6  127 (P <
.01) and 96.4  106 (P .01), and 150.8  124 (P <0.01) and 101.2  104 (P<0.01), respectively. Although the ABI
showed a slight increase in the treatment group, these differences were not statistically significant.
Conclusions: The results of this pilot study show that IPCFC improves walking distance in patients with stable
intermittent claudication. A significant increase in ICD and ACD was seen at 4 and 6 months of treatment, respectively,
and the improvement was sustained at 1 year. The combination of IPCFC with other treatment such as risk-factor
modification and daily exercise may prove useful in patients with peripheral arterial occlusive disease. It may be a useful
first line of therapy in patients with disabling claudication who are unfit for major reconstructive surgery. Improved
walking on long-term follow-up and experience from different centers may establish a role for this treatment modality in
the future. ( J Vasc Surg 2005;41:794-801.)Claudication is a disease predominantly affecting older
patients,1-3 with a higher incidence in men.4-6 Although
the natural history of claudication is benign, the progres-
sion of symptoms may necessitate intervention, either by
endovascular techniques or by conventional bypass graft-
ing.
Intermittent pneumatic compression using low pres-
sure (typically 50 mm Hg) is a widely accepted modality
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794for deep vein thrombosis prophylaxis.7,8 Although early
reports showed the efficacy of pneumatic compression in
increasing tissue perfusion in patients with peripheral
arterial occlusive disease (PAOD),9 it is only recently
that there has been a resurgence of interest in this
modality.10-14 Popliteal artery blood flow has been
shown to be increased by rapid, high-pressure calf com-
pression11 and by combined, rapid calf and foot com-
pression using high compression pressures13  100 mm
Hg applied rapidly (300 millisecond rise time). When
intermittent compression was applied to both the calf
and foot, popliteal artery blood flow increased nearly
threefold compared with foot compression alone.13 A
more recent study with intermittent pneumatic foot
compression (IPFC) alone has shown a marked improve-
ment in walking distance in patients with stable intermit-
tent claudication.14
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high-pressure IPFC in patients with stable claudication.We
describe the early clinical results of the use of IPCFC in
patients with stable claudication with reference to the end
points of improvement in the initial claudication distance
(ICD) (distance at which the patient initially feels pain or
discomfort in the legs), and improvement in the absolute
claudication distance (ACD) (distance at which the patient
stops walking because the pain or discomfort becomes
severe).
METHODS
Patients with symptoms suggestive of PAOD who pre-
sented to the vascular clinic at a single center were evaluated
for enrollment in this pilot study, which was approved by
and conducted in accordance with the local institutional
review board. Informed consent was obtained from all
patients before the study began. All patients had PAOD
diagnosed 6 to 12 months earlier and had stable claudica-
tion. The criteria for inclusion in the study were a resting
ABI 0.90, except in those with ABI 0.90 secondary to
distal incompressible vessels; a fall in the ABI by0.1 in the
affected limb on treadmill exercising (3.8 km/h at a 10°
gradient for 1 minute); and an ACD between 50 and 150
meters on treadmill exercise (3.8 km/h at a 10° gradient).
The ACD was measured during two screening visits 1
week apart, and patients whose ACD differed by 10
meters were eligible to join the study.
The exclusion criteria for the study included ischemic
or venous stasis ulcers; a history suggestive of rest pain;
myocardial infarction 6 months, cardiac arrhythmia, ex-
ercise-limiting congestive cardiac failure, or angina; pa-
tients being treated with rheologic agents, namely pentoxi-
fylline or cilostazol; the use of investigational drugs 6
months; or a history of a lower extremity revascularization
procedure.
A detailed history was obtained from all patients, fol-
lowed by clinical examination with assessment of pulses
(femoral/popliteal/dorsalis pedis and posterior tibial). A
resting and postexercise ABI (3.8 km/h at 10° gradient for
1 minute) was performed in all patients. The ABI was
calculated by dividing the highest systolic pressure in the
pedal artery by the highest brachial artery pressure, and the
postexercise ABI was performed as per a previously de-
scribed protocol.15 All patients were studied in two screen-
ing visits where they exercised on a treadmill (3.8 km/h at
10° gradient) for the measurement of the ICD and ACD.
The ICD was the distance that the patient could walk
before complaining of pain or discomfort in the affected
limb; the ACD was the distance that the patient could walk
before the severity of pain or discomfort caused the test to
be terminated. All patients were rested for 20 minutes
before the commencement of exercise for the measurement
of ICD and ACD. A stopwatch was used to measure the
time taken in seconds to reach the ICD (t1) and ACD (t2).
Given that the speed of the treadmill was 3.8 km/h, the
following calculations were used for determining the ICD
and ACD:Treadmill speed 3.8 km/h or 3800meters over 3600
seconds;
ICD (m)  3800  t1/3600  38 t1/36  1.06 t1;
ACD (m)  1.06 t2
A difference of 10 meters in the ACD in the two
screening visits excluded patients from the study. Alternate
patients who fulfilled the criteria for enrollment in the study
were randomized into either treatment with the ArtAssist
IPCFC device (ACI Medical, Inc., San Marcos, Calif) or
assigned to the control group.
Patients who were randomized to the treatment group
were encouraged to use the IPFCC device for an hour twice
daily, in the sitting position. This device had two pressure
cuffs, one of which was wrapped around the foot and
extended to the ankle, and another around the calf. Com-
pression was first applied to the foot and spread proximally
to the calf with air pulses delivered separately to the two
cuffs from a control unit. The pressure in each cuff was
rapidly inflated to the relatively high pressure of 120 mm
Hg, with an approximate 300-millisecond rise time and a
1-second delay between inflation of the foot and calf cuff.
The cuffs held the pressure for 3 seconds each before
deflating, foot first followed by the calf. The settings in the
unit provided for three cycles of compression per minute.
The compression pressure of 120 mm Hg and sequential
inflation with a 1-second delay, with the patient in the
sitting position, were adopted based on results from a
previous study.16 Additionally, all patients randomized to
treatment were also encouraged to exercise daily. Patients
randomized to the control group were encouraged to
exercise.
During the follow-up period, patients were studied at
1, 2, 3, 4, 6, and 12 months. The resting ABI, ICD, and
ACD were measured in all patients during these visits.
Importantly, in patients who failed to attend for follow-up,
telephone follow-up was obtained in terms of overall well
being, device usage in the treatment group, adherence to
daily exercise in the control group, and any changes in the
walking distance.
Statistical analysis. The percent changes from base-
line for ICD and ACD were calculated for each patient at
each study visit and the mean  standard deviation (SD),
standard error (SE), and median were calculated for the
control and treatment groups. The groups were compared
using a Wilcoxon rank sum test at a 5% significance level.
No adjustments were made for multiple testing.
The goal of data analysis was to assess differences in
outcomes between the two treatment groups over the
entire study period. Loss of information from subjects who
failed to attend one or more follow-up visits was minimized
by applying the “last observation carried forward” (LOCF)
method to missing data. This technique, sometimes used in
randomized clinical trials,17 uses measurements recorded
from the last observed period before a missed visit to
replace missing data in subsequent follow-ups. LOCF as-
sumes that outcomes remain constant since the last ob-
served value. Because the experimental treatment in this
study was expected to induce a change in the ICD and
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tion of the treatment, and no substantial change was ex-
pected in the control group, this technique for handling
missing values might have been conservative.18
Additional statistical testing was performed using
Kaplan-Meier estimation and log-rank tests to determine if
there were differences between the treatment and control
groups with respect to the ICD and ACD. JMP software,
version 5.1 (SAS Institute Inc., Cary, NC, 2003), was used
for statistical analysis.
RESULTS
A select group of 34 patients were screened and 30
were recruited into the study (15 to the treatment group
with the ArtAssist IPFCC device, and 15 served as con-
trols). Reasons for exclusion included the ACD 150
meters in two patients, inability to attend for follow-up in
one, and severe hip pain with inability to exercise in an-
other. All subjects were men. The mean age of the control
and treatment groups was 70.7  9 and 70.4  7 years.
The clinical examination showed that the arterial disease
was infrainguinal in all patients. The risk factors (diabetes,
hypertension, hypercholesterolemia needing treatment and
smoking), ICD, and ACD for patients recruited into the
control or treatment groups are summarized in Table I.
Complete follow-up for all patients was available at 2
months; after this, the number of patients attending for
follow-up in the treatment and control groups at 3, 4, 6,
and 12 months were 12 and 12, 11 and 9, 10 and 6, and 6
and 5, respectively.
As already mentioned, telephone follow-up was ob-
tained from all patients who failed to attend follow-up.
Table I. Baseline characteristics by study group at
enrollment in study
Control
Group
Treatment
Group
Variable % (n)* % (n)* P†
Age 70.7  9.0 70.4  7.2 .8843
Type II diabetes
mellitus
46.7 (7) 46.7 (7) 1.0000
Hypertension 66.7 (10) 60.0 (9) 1.0000
Hypercholesterolemia 53.3 (8) 53.3 (8) 1.0000
Current smoker 26.7 (4) 40.0 (6) .6985
ICD (m) 68.4  17.3 55.8  14.9 .0588
ACD (m) 103.9  27.5 86.7  18.9 .0887
ABI-RT 0.63  0.20 0.70  0.13 .3395
ABI-LT 0.64  0.15 0.58  0.11 .2798
ICD (m), Initial claudication distance in meters; ACD (m), absolute clau-
dication distance in meters; ABI, ankle/brachial index; RT, right; LT, left.
*Data are mean  standard deviation
†TheMann-WhitneyU test P value was applied for continuous variables and
Pearson’s 2test Pvalue with Yates’ correction was applied for categorical
variables. There were no statistically significant differences between the two
groups at baseline. Only two marginally significant differences (P  .1) for
ICD and ACD were seen and the differences were in favor for the control
group.During the course of telephone follow-up, patients in thetreatment group reported that the improvement in walking
distance was sustained, whereas those in the control group
reported no change since the last visit. The percent change
from baseline measurements for the ICD and ACD in the
treatment and control groups for each study visit is sum-
marized in Table II, and in Figs 1 and 2.
A rapid improvement in ICD that was seen between 2
and 4 months was sustained at 6 months and 1 year (Fig 1).
For the ACD, the improvement was rapid until 6 months,
with a slight increase at 1 year (Fig 2). Using Kaplan-Meier
estimation and the log-rank tests at a 5% significance level,
we found significant differences for ICD at all times in the
treatment and control groups except at 1 and 12 months,
although P  .06 at 12 months was close to being signifi-
cant (Figs 3, A; 4, A; and 5, A). Significant differences in
ACD between the treatment and control groups occurred
only at 2 months, with P.07, .24, and .56 at 4, 6, and 12
months, respectively (Figs 3, B; 4, B; and 5, B).
The analysis using LOCF to replace the missing values
showed significant differences at all times (1, 2, 3, 4, 6, and
12 months) for both ICD and ACD. We believe that the
differences are, at least in part, likely due to the reduced
sample size during follow-up visits and also to “overachiev-
ers” in the treatment group dropping out of the study early
and not attending for follow-up, as the analysis of ICD and
ACD in patients dropping out of the study showed inter-
esting trends. Four of the five patients in the treatment
group who dropped out of the study at 6 months showed a
significant improvement in walking distance, with an aver-
age increase in ICD and ACD of 117% and 60% compared
with baseline; only one patient in this group showed a
decrease in ICD (–4%) and ACD (–1%).
At the end of 1 year, four patients in the treatment
group who had attended follow-up at 6 months dropped
out of the study. Analysis of the walking distance in these
patients at 6 months showed that they were overachievers
who had performed better than others in their group, with
a percent increase of 298% in ICD and 229% in ACD. The
analysis of walking distances in patients from the control
group who dropped out of the study showed either no
improvement or a slight decrease from baseline for the ICD
and ACD.
With the Wilcoxon rank sum test (Mann-Whitney U
test), 33 subjects per treatment group are needed to yield
80% power to detect a true probability of 0.70 that an ACD
or ICD in the treatment group will be higher than an ACD
or ICD in the control group. In our study, the number of
people in the control and treatment groups was 6 and 10 at
6 months, and 5 and 6 at 12 months. The probability was
60% that an ACD from the treatment group was greater
than an ACD from the control group and 87% for the ICD.
DISCUSSION
The role of intermittent compression in the prophy-
laxis of deep vein thrombosis is well established.7,8 Early
clinical reports showed the beneficial effects of compres-
sion therapy in the treatment of patients with PAOD9 ;
however, the lack of physiologic quantification of im-
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tissue perfusion, delayed further investigation of this
treatment modality. It was not until 1978 that Gaskell
and Parrot,19 with the use of radioactive Xe133 scan-
TableII. Percent change from baseline measurements in
in the control and treatment groups
Control group
% Change from baseline
Variable in
meters Mean  SD SE Median (range)
ICD (1-mon) 3.2  13.4 3.5 4.6 (–29.5, 27.0)
ACD (1-mon) 3.8  5.9 1.5 3.8 (9.0, 16.4)
ICD (2-mon) –1.6  11.2 2.9 –2.3 (–22.5, 22.6)
ACD (2-mon) 3.3  8.9 2.3 5.3 (–16.5, 19.6)
ICD (3-mon) 1.5  20.9 5.4 2.9 (–30.5,59.7)
ACD (3-mon) 4.6  20.4 5.3 5.4 (–44.4, 42.6)
ICD (4-mon) 2.2  18.0 4.6 4.3 (–30.5, 33.33)
ACD (4-mo) 2.3  18.5 4.8 5.4 (–44.4, 39.4)
ICD (6-mon) 2.9  17.5 4.5 4.3 (–30.5, 33.33)
ACD (6-mon) 5.2  20.2 5.2 7.2 (–44.4, 46.0)
ICD (12-mon) 3.6  18.3 4.7 5.8 (–30.5, 33.3)
ACD (12-mon) 5.8  20.4 5.2 7.2 (–44.4, 40.5)
ICD, Initial claudication distance in meters; ACD, absolute claudication di
* Wilcoxon rank sum test P value
Fig 1. Percent changes in the initial claudication distanc
of the mean) (*P value).ning, demonstrated that mechanical compression in-creased flow in the limbs of patients with arteriopathy in
the sitting position.
Recent improvements in noninvasive color flow duplex
imaging have enabled quantification of popliteal artery
l claudication distance and absolute claudication distance
Treatment group
% Change from baseline
Mean  SD SE Median (range) P*
53.3  80.8 20.9 26.0 (12.1, 286.5) .0121
29.6  34.4 8.9 21.3 (11.5, 104.2) .0327
98.3  93.7 24.2 93.3 (3.9, 300.0) .0002
72.2  71.7 18.5 49.3 (1.2, 280.0) .0001
122.2  112.6 29.1 86.9 (3.9, 351.2) .0001
79.2  82.6 21.3 52.0 (1.2, 275.0) .0001
137.1  128.0 33.1 86.9 (3.9, 392.3) .0001
84.3  81.7 21.1 56.2 (1.2, 275.0) .0001
140.6  127.0 32.8 88.0 (3.9, 392.3) .0001
96.4  105.7 27.3 66.8 (1.2, 384.0) .0001
150.8  123.7 31.9 106.0 (3.9, 392.3) .0001
101.2  103.7 26.8 72.8 (1.2, 384.0) .0001
in meters; SD, standard deviation; SE, standard error of mean.
he treatment and control group (mean standard errorinitia
stancee in tblood flow and studies have demonstrated increased flow
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py.11,13 Additionally, the beneficial effects of compression
therapy in improving tissue perfusion to the foot have also
been demonstrated with the use of laser Doppler scan-
ning.12,13,20
Numerous mechanisms have been postulated for the
increase in blood flow after this form of intermittent pneu-
matic compression therapy. In the sitting position, hydro-
static pressure causes an increase in arterial and venous
pressures, and after rapid pneumatic compression, venous
pressure is decreased to almost zero, with little or no
decrease in arterial pressure. The percent increase in arte-
riovenous pressure gradient results in a similar increase in
flow according to the equation: Flow  Pressure/Resis-
tance.
Because the compression phase is significantly shorter
than the relaxation phase, the increased flow is sustained
while the veins slowly refill. Recent work has shown that the
use of a compression pressure of 120 mm Hg with a
1-second delay between foot and calf compression leads to
optimal lowering of venous pressures.16
The venoarteriolar reflex (VAR) exists as a protective
mechanism that causes vasoconstriction and prevents swell-
ing that might otherwise occur after an increase in the
venous pressure due to postural changes involving the
limb.21 The VAR causes contraction of precapillary sphinc-
ters, resulting in an increase in peripheral vascular resistance
with a concomitant decrease in arterial blood flow.22 The
use of pneumatic compression decreases venous pressure,
which momentarily abolishes the VAR.23
Vasodilatation at the microcirculatory level decreases
Fig 2. Percent changes in the absolute claudication dis
error of mean) (*P value).peripheral resistance, and flow therefore increases, based onthe previous flow equation. The increased flow in turn aids
in the development of collaterals with improved limb per-
fusion. Other postulated mechanisms for the increase in
blood flow include the production of endothelial-derived
vasodilating factors such as nitrous oxide and prostacyclin
as a result of increased shear stress.24,25
Although intermittent pneumatic compression therapy
has been shown to increase popliteal artery blood flow in
patients with angiographically proven superficial femoral
artery stenosis,13 a more recent study has documented
increased tissue perfusion after use in patients with distal
infrapopliteal disease.20 In our study, PAOD was docu-
mented by clinical examination and the resting and postex-
ercise ABI. The ICD and ACD for patients recruited into
the study in the control and treatment group inmeters were
68.4  17 and 55.8  14.9, and 103.9  27 and 86.7 
18.9, respectively. The differences in ICD and ACD were
marginally significant and in favor of the control group.
The ICD and ACD remained unchanged in the control
group (exercise only), whereas IPCFC and daily exercise
resulted in significant increases in the treatment group. The
ICD increases in the treatment group were rapid until 4
months, and the increases thereafter, although minimal,
were sustained at 6 months and 1 year (Fig 1). The ACD,
on the other hand, showed significant increases at each
study visit until 6 months, but only a minimal increase
thereafter at 1 year (Fig 2). Although, patients in the
treatment group used the device for up to a year, extended
use6 months produced only a marginal increase in walk-
ing. The effects of withdrawal therapy are not addressed in
in the treatment and control groups (mean standardtanceour pilot study.
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lost for patients who failed to attend for follow-up. How-
ever, an analysis of walking distance data in patients in the
treatment group who dropped out showed that they were
significant overachievers, with a percent increase of 298% in
ICD and 229% in ACD compared with baseline. It is
therefore logical to assume that with these increases in
walking distances, these patients did not feel the need to
attend further follow-up. The analysis of walking distance
in patients in the control group who dropped out showed
either no improvement or a slight deterioration from base-
line ICD and ACD.
A recent study has demonstrated significant improve-
ment in ICD and ACD by using intermittent pneumatic
foot compression (IPFC) alone.14 This study involved the
same treadmill protocol as ours and required patients to use
the IPFC device for 4 hours daily over 4.5 months and with
follow-up available to 1 year. This study has shown compa-
rable improvement in walking distances with ours, but the
increases in ICD and ACD in our study were obtained with
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Fig 3. A. Proportion of subjects walking at least the specified
initial claudication distance (ICD)in meters at the 4-month fol-
low-up visit. Control vs treatment group, P  .01. B. Proportion
of subjects walking at least the specified absolute claudication
distance (ACD) in meters at the 4-month follow-up visit. Control
vs treatment group, P  .07.half the daily “dose” of compression therapy. This findingmay, in fact, demonstrate the combined value of foot and
calf compression. Furthermore, this would also be in keep-
ing with the finding that combined foot and calf compres-
sion increases popliteal artery blood flow three times more
than foot compression alone.13
An interesting finding in the study that used IPFC 14
was that the maximum increase in ACDwas seen in the first
3 months after treatment, with little improvement thereaf-
ter. Also, a significant increase in the ABI was seen at the
end of 3 and 5 months after treatment with IPFC. In our
study with IPCFC, the ABI showed an increase in the
treatment group, although this did not reach statistical
significance compared with baseline.
The traditional treatment of claudication includes a
modification of risk factors (eg, smoking cessation) and
daily exercise. Although unsupervised exercise alone pro-
duces insignificant improvement in walking distance,26 su-
pervised exercise programs have been shown to be effective,
with significant improvement in walking.27 However, these
programs may not be readily available at most medical
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Fig 4. A. Proportion of subjects walking at least the specified
initial claudication distance (ICD) in meters at the 6-month fol-
low-up visit. Control vs treatment group, P  .01. B. Proportion
of subjects walking at least the specified absolute claudication
distance (ACD) in meters at the 6-month follow-up visit. Control
vs treatment group, P  .24.centers and are also expensive to run. The use of a portable
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these patients to receive treatment at home.
A built-in timer in these devices that is hidden from the
patient allowed us to determine the extent of patient com-
pliance and usage. This study did not require patients to
maintain an activity log or complete a physical activity
questionnaire, leading to the argument that the improve-
ment in walking distance in the treatment group might
represent a placebo effect, with the benefit resulting from a
significant expectation of improvement. Importantly, it is
interesting to note that the increases in walking distance in
our study and with the use of IPFC14 appear to be compa-
rable to those obtained with pharmacologic modalities28
and with no side effects reported.
The early results of IPCFC treatment in patients with
claudication in our pilot study have been encouraging, and the
long-term results are still awaited. If the improvements in
walking distances are sustained, the combination of intermit-
tent pneumatic calf and foot compression with other treat-
ment such as modification of risk factors and daily exercise
may prove to be useful in patients with PAOD. It may also
Fig 5. A. Proportion of subjects walking at least the specified
initial claudication distance (ICD) in meters at the 12-month
follow-up visit. Control vs treatment group, P  .06. B. Propor-
tion of subjects walking at least the specified absolute claudication
distance (ACD) in meters at the 12-month follow-up visit. Con-
trol vs treatment group, P  .56.prove useful as the first line of therapy in the treatment ofpatients with risk factors and disabling claudication who may
otherwise be unfit formajor reconstructive surgery andwhose
quality of life is severely impaired.29,30 Experiences from dif-
ferent centers and larger studies may establish a role for this
treatment modality in the future.
We thank Sylvia Wiley for assistance with the prepara-
tion of this manuscript and ACI Medical, Inc, San Marcos,
Calif, for providing the ArtAssist AA-1000 compression
devices used in the study.
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